Expression of PARP-1 in Multiple Sclerosis Patients

Expression of PARP-1 in Optic Neuritis of Multiple Sclerosis Patients

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT05196425

Enrollment

Registered

2022-01-19

Start date

2021-08-01

Completion date

2022-04-30

Last updated

2025-05-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Multiple Sclerosis

Keywords

Optic neuritis-Multiple sclerosis-PARP-1

Brief summary

This study will explore the expression of PARP-1 in optic neuritis of multiple sclerosis patients. The data will be collected from Sohag University hospital in the period from the start of August 2021 to the end of December 2021. The study protocol will be approved by the Scientific Research Ethical Committee, Faculty of Medicine, Sohag University.

Interventions

GENETICBlood sampling

Blood sample for detection of PARP-1 gene and correlate to changes of the optic disc, RNFL and GCC layers of the retina of MS patients

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

DIAGNOSTIC

Masking

SINGLE (Investigator)

Eligibility

Sex/Gender

ALL

Age

20 Years to 45 Years

Healthy volunteers

Yes

Inclusion criteria

* Patients with multiple sclerosis with or without optic neuritis Multiple sclerosis will be diagnosed according to the McDonald criteria

Exclusion criteria

* • Isolated optic neuritis.

Design outcomes

Primary

Measure	Time frame	Description
measure PARP-1 mRNA	2 weeks	measure PARP-1 mRNA

Secondary

Measure	Time frame	Description
Optic nerve, RNFL and GCC layer affection by MS	2 weeks	Optic nerve Retinal nerve fibre layer (RNFL) in um ) and Ganglion cell complex (GCC) layer affection in um by MS in correlation to PARP-1 mRNA

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026